Heat-Activated Target Therapy (Radiotherapy + Hyperthermia + Lyso-Thermosensitive Liposomal Doxorubicin) of Local-Regional Relapse in Breast Cancer Patients

Trial Profile

Heat-Activated Target Therapy (Radiotherapy + Hyperthermia + Lyso-Thermosensitive Liposomal Doxorubicin) of Local-Regional Relapse in Breast Cancer Patients

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Doxorubicin liposomal (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Euro-DIGNITY
  • Sponsors Celsion Corporation
  • Most Recent Events

    • 30 May 2017 Planned End Date changed from 1 Nov 2019 to 1 Feb 2020.
    • 30 May 2017 Planned primary completion date changed from 1 Sep 2019 to 1 Dec 2019.
    • 30 May 2017 Planned initiation date changed from 1 Apr 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top